Dear readers of, please forgive the disruption. needs about $36850 in 2023. In 2022 we received donations from third parties of about $ 13870. Unfortunately, 99.8% of our readers do not donate. If everyone who reads this request makes a small contribution, our fundraising campaign for 2023 would be over after a few days. This donation request is displayed 18,000 times a week, but only 40 people donate. If you find useful, please take a minute and support with your donation. Thank you!

Since 01.06.2021 is supported by the non-profit ADxS e.V..

$7996 of $36850 - as of 2023-05-01
Header Image
1. Control ranges through dopamine


1. Control ranges through dopamine

1.1. Behavior regulated by dopamine

  • Drive
  • Motivation
    • Dopamine activates the striatum12
      Dopamine deficiency in the striatum can cause anhedonia (disinterest)
    • D2 receptors in the reinforcing system (striatum) are involved in dysfunctional reward behavior3
    • Dopamine appears to primarily regulate wanting, rather than liking or learning4
  • Attention
  • Activity
  • Fine motor skills1
    • Dopamine deficiency causes control problems: imprecise motor activity on the one hand (spidery writing) and overshooting motor activity on the other (hyperactivity)
    • D1 receptors in the PFC are involved in dysfunctional inhibition3
  • Behavioral Control1
    • Situational recall of behaviors, especially in response to emotions6
    • Control of the intensity of the stress response78
  • Affect Control7
  • Synaptic plasticity91011121314
    • Among other things, the PFC forms long-term memory for abstract rules or strategies using long-term potentiation (LTP) as a form of synaptic plasticity.
    • Medium tonic dopamine levels facilitate the induction of LTP, too high or too low dopamine levels worsen it (inverted U function)
    • Induction of LTD by low-frequency stimuli occurs independently of tonic dopamine by endogenous, phasically released dopamine during stimuli.
      LTP is inhibited by
      • Blockade of dopamine receptors during stimuli
      • Inhibition of dopamine transporter activity.
  • Eye blink rate
    • Dopamine increases the blink rate; dopamine deficiency decreases it.1516
    • Eyelid blink rate is discussed as a biomarker of striatal D2 and D3 receptor activity.1718
    • A decreased eyelid blink rate has been observed in ADHD,1920 which increased with stimulants.20 One study found no relevant difference in eyelid blink rate in children with ADHD.21 One study, which does not reflect whether the ADHD subjects were medicated, found higher eyelid blink rates in children with ADHD.22 One study found increased eyelid blink rates in children with ADHD who had been unmedicated for 24 hours in boys only.23
    • In healthy adults, decreased blink rate correlated with impulsivity.24
  • Immune system25
    • Overview in Broome et al26
    • B lymphocytes, T lymphocytes, natural killer cells, dendritic cells, and macrophages possess dopamine, norepinephrine, and epinephrine receptors.
      • They can be independent of the system of nerve cells26
        • Produce dopamine
        • Store dopamine
        • Resume dopamine
        • Break down dopamine
        • Lymphocytes also norepinephrine
      • Dopamine is involved in the regulation of inflammation. Depending on the dopamine level and dopamine receptor, dopamine acts27
        • pro-inflammatory
          • at high-affinity dopamine receptors
            • D3
            • D5
        • anti-inflammatory.
          • at low-affinity dopamine receptors
            • D1
            • D2
      • Glial cells
        • Regulate, among other things, central neuroinflammation in the brain26
          • CNS neuroinflammation: inflammatory processes in the neuronal tissues of the brain
          • Regulated by production of cytokines, chemokines, reactive oxygen species and secondary messengers by microglia and astrocytes
          • Is associated with most CNS pathologies characterized by abnormal dopaminergic signaling
            • Among others:
              • Parkinson’s
              • Schizophrenia
              • Mood disorders
            • The chronic neuroinflammation that occurs in these disorders promotes infiltration of peripheral immune cells of the adaptive and innate immune systems into the site of inflammation
            • Dopamine acts in glia as well as in peripheral immune cells as a neurotransmitter and as an immune transmitter.
        • Microglia
          • Save unknown
          • Receptors: D1, D2, D3, D4
          • Microglia types:
            • M0 phenotype
              • Dormant
            • M1
              • Classically activated
              • Neurotoxic
              • Pro-inflammatory
            • M2a
              • Alternatively activated
              • Neuroprotective
              • Anti-inflammatory
            • M2b
              • Type II alternative activation
            • M2c
              • Acquired deactivation
        • Astrocytes
          • Receptors: D1, D2, D3, D4, D5
      • Cells of the innate immune system:
        • Macrophages
          • Degradation unknown
          • Receptors: D1, D2, D3, D4, D5
        • Dendritic cells
          • Receptors: D1, D2, D3, D4, D5
        • Neutrophils
          • Receptors: D1, D2, D3, D4, D5
        • NK cells (natural killer cells)28
          • Receptors:
            • D1 (?) and D5: enhanced cytotoxic activity
            • D5: Inhibition of cell proliferation and IFN-γ production in activated (not in resting) NK cells
            • D2, D3, and D4: attenuated cytotoxic activity (Talhada et al., 2018).
      • Cells of the acquired immune system:
        • Oligodendrocytes
          • Synthesis, storage, reuptake, degradation unknown
          • Receptors: D2, D3
        • Monocytes
          • Degradation unknown
          • Receptors: D1, D2, D3, D4, D5
        • T lymphocytes
          • Receptors: D1, D2, D3, D4, D5
        • B lymphocytes
          • Resumption unknown
          • Receptors: D1, D2, D3, D4, D5
        • Eosinophils
          • Synthesis, storage, recovery unknown
          • Receptors: D1, D2, D3, D4, D5
        • Mast cells
          • Resumption and dismantling unknown

Dopamine modulates non-dopaminergic signaling. Disturbances in dopamine balance can impair glutamatergic and GABAergic signal transmission.29

Dopamine can increase and decrease the excitability of mPFC neurons-suggesting differential modulation by dopamine depending on mPFC cell type or projection target.30

In principle, the firing rate of dopaminergic neurons increases with anticipated reward. However, there also seem to be dopaminergic neurons that become more active during stress.31

Acute stress increases dopamine and norepinephrine even in the presence of coexisting chronic stress

In any case, in purely acute stress, increased levels of dopamine (+ 54 %) and norepinephrine (+ 50 %) were found in the mPFC. In existing chronic stress, added acute stress increased dopamine by 42% and norepinephrine by 92%.32 Diazepam reduced the increase only in pure acute stress in dopamine to + 17% and in norepinephrine to + 42%. In existing chronic stress, diazepam did not reduce dopamine and norepinephrine changes on added acute stress. Note: “Chronic stress” in this study was cold exposure of three to four weeks. In our opinion, the reduced dopamine and norepinephrine levels in chronic stress, which we have described many times in this project, are consequences of a significantly longer exposure to stress.

1.2. Dopamine and melatonin: waking/sleeping behavior, circadian rhythm

Dopamine, together with melatonin, is involved in the regulation of fatigue and sleep.

The dopaminergic system is influenced by the circadian system.3334
Dopamine is produced rhythmically in the amacrine cells of the retina. The retina is controlled by dopamine as well as by melatonin. The retina transmits light information to the suprachiasmatic nucleus, which is the master biological clock. The suprachiasmatic nucleus sends timing information for rhythmic regulation of dopaminergic brain regions and the behavior controlled by them (locomotion, motivation). Dopamine produced in the substantia nigra and ventral tegmentum may be rhythmically regulated by the suprachiasmatic nucleus via various neural pathways (including by means of the orexin system or the medial preoptic nucleus of the hypothalamus).35

The intrinsically photosensitive retinal ganglion cells (ipRGCs) of the M1 type (which are associated with the amacrine cells36 modulate melatonin and dopamine release in addition to the pupillary reflex.37 Unlike rod and cone photoreceptor cells in the retina, which are responsible for night and color vision, ipRGCs are responsible for non-imaging perception of light intensity. These cells are thus likely to be involved in hypersensitivity to light due to high sensitivity.
The ipRGCs project to the nucleus suprachiasmaticus via the retinohypothalamic tract.

Impaired dopamine synthesis in the retina leads to impaired circadian rhythm functions.38 Dopamine and melatonin inhibit each other.39 Dopamine is released during the day and inhibits melatonin secretion, and conversely, melatonin (which is inhibited by daylight) is released in the evening and at night and inhibits dopamine release.4041

The photopigment melanopsin in ipRGCs is most sensitive to blue light.4243 In addition to projecting to the suprachiasmatic nucleus, ipRGCs also project to sleep-promoting neurons in the ventrolateral preoptic nucleus and superior colliculus.44 The suprachiasmatic nucleus synchronizes multiple peripheral clocks that together control circadian rhythmicity.45

A dopamine deficiency (as is typical for ADHD) could therefore cause too little melatonin inhibition during the day. This could possibly explain the severe daytime sleepiness reported by some ADHD patients. Difficulty falling asleep, on the other hand, is more likely to result from an impairment of the circadian rhythm and a resulting existing melatonin deficiency and more likely to occur despite the lower dopamine level in ADHD than to follow from it.

1.3. Other influences of dopamine

Dopamine influences very many areas of the brain. At this point we begin to collect these mechanisms.

1.3.1. DARPP-32

Dopamine/adenosine-3’,5’-monophosphate-regulated phosphoprotein 32 (DARPP-32) is a potent inhibitor of calcium-independent serine/threonine phosphatases.
It is a phosphoprotein that is phosphorylated by dopamine through protein kinase A and is found in D1 dopamine receptors). The phosphorylation state of DARPP-32 can be regulated by dopamine and by cyclic AMP. DARPP-32 appears to be relevant in mediating certain effects of dopamine on dopaminoceptive cells.4647
DARP-32 can be found in

  • Amygdala
  • Nucleus Caudatus / Putamen
  • Nucleus accumbens.

1.3.1. Nf-kB

Dopamine inhibits nN-kB.

  1. Simchen, Helga:; dort: was bewirken die Botenstoffe


  3. Krause, Krause (2014): ADHS im Erwachsenenalter – Symptome, Differentialdiagnose, Therapie; Schattauer, Seite 25 / 26, mit weiteren Nachweisen

  4. Berridge (2007): The debate over dopamine’s role in reward: the case for incentive salience. Psychopharmacology (Berl). 2007 Apr;191(3):391-431. doi: 10.1007/s00213-006-0578-x. PMID: 17072591.

  5. Oades, Röpcke (2000).: Neurobiologische Grundlagen der Aufmerksamkeit: „Über die Freiheit der Wahl“. Sprache – Stimme – Gehör 24 (2000) 49 – 56

  6. Rensing, Koch, Rippe, Rippe (2006): Der Mensch im Stress; Psyche, Körper, Moleküle, Kapitel 4: neurobiologische Grundlagen von Stressreaktionen, Seite 82

  7. Rensing, Koch, Rippe, Rippe (2006): Der Mensch im Stress; Psyche, Körper, Moleküle, Kapitel 4: neurobiologische Grundlagen von Stressreaktionen, Seite 82

  8. Deutch, Clark, Roth (1990): Prefrontal cortical dopamine depletion enhances the responsiveness of mesolimbic dopamine neurons to stress. Brain Res. 1990 Jun 25;521(1-2):311-5.

  9. Otani, Bai, Blot (2015): Dopaminergic modulation of synaptic plasticity in rat prefrontal neurons. Neurosci Bull. 2015 Apr;31(2):183-90. doi: 10.1007/s12264-014-1507-3.

  10. Cohen, Braver, Brown (2002): Computational perspectives on dopamine function in prefrontal cortex. Curr Opin Neurobiol. 2002 Apr;12(2):223-9.

  11. Bao, Chan, Merzenich (2001): Cortical remodelling induced by activity of ventral tegmental dopamine neurons. Nature volume 412, pages79–83, 2001

  12. Gurden, Takita, Jay (2000): Essential role of D1 but not D2 receptors in the NMDA receptor-dependent long-term potentiation at hippocampal-prefrontal cortex synapses in vivo. J Neurosci. 2000 Nov;20(22) RC106. doi:10.1523/JNEUROSCI.20-22-j0003.2000. PMID: 11069975; PMCID: PMC6773154.

  13. Law-Tho, Desce, Crepel (1995): Dopamine favours the emergence of long-term depression versus long-term potentiation in slices of rat prefrontal cortex, Neuroscience Letters, Volume 188, Issue 2, 1995, Pages 125-128, ISSN 0304-3940,

  14. Otani, Blond, Desce, Crépel (1998): Dopamine facilitates long-term depression of glutamatergic transmission in rat prefrontal cortex, Neuroscience, Volume 85, Issue 3, 1998, Pages 669-676, ISSN 0306-4522,

  15. Müller (2007): Dopamin und kognitive Handlungssteuerung: Flexibilität und Stabilität in einem Set-Shifting Paradigma. Dissertation

  16. Roberts, Symons, Johnson, Hatton, Boccia (2005): Blink rate in boys with fragile X syndrome: preliminary evidence for altered dopamine function. J Intellect Disabil Res. 2005 Sep;49(Pt 9):647-56. doi: 10.1111/j.1365-2788.2005.00713.x. PMID: 16108982.

  17. Groman, James, Seu, Tran, Clark, Harpster, Crawford, Burtner, Feiler, Roth, Elsworth, London, Jentsch (2014): In the blink of an eye: relating positive-feedback sensitivity to striatal dopamine D2-like receptors through blink rate. J Neurosci. 2014 Oct 22;34(43):14443-54. doi: 10.1523/JNEUROSCI.3037-14.2014. PMID: 25339755; PMCID: PMC4205561.

  18. [Mathar, Wiehler, Chakroun, Goltz, Peters (2018): A potential link between gambling addiction severity and central dopamine levels: Evidence from spontaneous eye blink rates. Sci Rep. 2018 Sep 6;8(1):13371. doi: 10.1038/s41598-018-31531-1. PMID: 30190487; PMCID: PMC6127194.)](

  19. Konrad, Gauggel, Schurek (2003): Catecholamine functioning in children with traumatic brain injuries and children with attention-deficit/hyperactivity disorder. Brain Res Cogn Brain Res. 2003 May;16(3):425-33. doi: 10.1016/s0926-6410(03)00057-0. PMID: 12706222. n = 83

  20. Caplan, Guthrie, Komo (1996): Blink rate in children with attention-deficit-hyperactivity disorder. Biol Psychiatry. 1996 Jun 15;39(12):1032-8. doi: 10.1016/0006-3223(95)00315-0. PMID: 8780838. n = 75

  21. Groen, Börger, Koerts, Thome, Tucha (2017): Blink rate and blink timing in children with ADHD and the influence of stimulant medication. J Neural Transm (Vienna). 2017 Feb;124(Suppl 1):27-38. doi: 10.1007/s00702-015-1457-6. PMID: 26471801; PMCID: PMC5281678. n = 50

  22. Baijot, Slama, Söderlund, Dan, Deltenre, Colin, Deconinck (2016): Neuropsychological and neurophysiological benefits from white noise in children with and without ADHD. Behav Brain Funct. 2016 Mar 15;12(1):11. doi: 10.1186/s12993-016-0095-y. PMID: 26979812; PMCID: PMC4791764.

  23. Tantillo, Kesick, Hynd, Dishman (2002): The effects of exercise on children with attention-deficit hyperactivity disorder. Med Sci Sports Exerc. 2002 Feb;34(2):203-12. doi: 10.1097/00005768-200202000-00004. PMID: 11828226. n = 18

  24. Korponay, Dentico, Kral, Ly, Kruis, Goldman, Lutz, Davidson (2018): Neurobiological correlates of impulsivity in healthy adults: Lower prefrontal gray matter volume and spontaneous eye-blink rate but greater resting-state functional connectivity in basal ganglia-thalamo-cortical circuitry. Neuroimage. 2017 Aug 15;157:288-296. doi: 10.1016/j.neuroimage.2017.06.015. Erratum in: Neuroimage. 2018 Feb 15;167:505. PMID: 28602816; PMCID: PMC5600835. n = 105

  25. Wolf, Calabrese (2020): Stressmedizin & Stresspsychologie; Seite 302

  26. Broome, Louangaphay, Keay, Leggio, Musumeci, Castorina (2020): Dopamine: an immune transmitter. Neural Regen Res. 2020 Dec;15(12):2173-2185. doi: 10.4103/1673-5374.284976. PMID: 32594028; PMCID: PMC7749467. REVIEW

  27. Pacheco, Contreras, Zouali (2014): The dopaminergic system in autoimmune diseases. Front Immunol. 2014 Mar 21;5:117. doi: 10.3389/fimmu.2014.00117. PMID: 24711809; PMCID: PMC3968755.

  28. Talhada, Rabenstein, Ruscher (2018): The role of dopaminergic immune cell signalling in poststroke inflammation. Ther Adv Neurol Disord. 2018 May 10;11:1756286418774225. doi: 10.1177/1756286418774225. PMID: 29774058; PMCID: PMC5952273. REVIEW

  29. Sagvolden, Johansen, Aase, Russell (2005): A dynamic developmental theory of attention-deficit/hyperactivity disorder (ADHD) predominantly hyperactive/impulsive and combined subtypes. Behav Brain Sci. 2005 Jun;28(3):397-419; discussion 419-68.

  30. Weele, Siciliano, Tye (2018): Dopamine tunes prefrontal outputs to orchestrate aversive processing. Brain Res. 2018 Dec 1. pii: S0006-8993(18)30610-3. doi: 10.1016/j.brainres.2018.11.044. Seite 30

  31. Arnsten (2009): Stress signalling pathways that impair prefrontal cortex structure and function. Nat Rev Neurosci. 2009 Jun;10(6):410-22. doi: 10.1038/nrn2648.

  32. Finlay, Zigmond, Abercrombie (1995): Increased dopamine and norepinephrine release in medial prefrontal cortex induced by acute and chronic stress: effects of diazepam. Neuroscience. 1995 Feb;64(3):619-28.

  33. Parekh, Ozburn, McClung (2015): Circadian clock genes: effects on dopamine, reward and addiction. Alcohol. 2015 Jun;49(4):341-9. doi: 10.1016/j.alcohol.2014.09.034.

  34. Baltazar, Coolen, Webb (2013): Diurnal rhythms in neural activation in the mesolimbic reward system: critical role of the medial prefrontal cortex. Eur J Neurosci. 2013 Jul;38(2):2319-27. doi: 10.1111/ejn.12224.

  35. Mendoza, Challet (2014): Circadian insights into dopamine mechanisms. Neuroscience. 2014 Dec 12;282:230-42. doi: 10.1016/j.neuroscience.2014.07.081.

  36. Stone, Pardue, Iuvone, Khurana (2013): Pharmacology of myopia and potential role for intrinsic retinal circadian rhythms. Exp Eye Res. 2013 Sep;114:35-47. doi: 10.1016/j.exer.2013.01.001. PMID: 23313151; PMCID: PMC3636148.)

  37. Schmidt, Kofuji (2009): Functional and morphological differences among intrinsically photosensitive retinal ganglion cells. J Neurosci. 2009 Jan 14;29(2):476-82. doi: 10.1523/JNEUROSCI.4117-08.2009. PMID: 19144848; PMCID: PMC2752349.

  38. Wirz-Justice, Wever, Aschoff (2004): Seasonality in freerunning circadian rhythms in man. Naturwissenschaften. 1984 Jun;71(6):316-9.

  39. Green, Besharse (2004): Retinal circadian clocks and control of retinal physiology. J Biol Rhythms. 2004 Apr;19(2):91-102.

  40. Stone, Pardue, Iuvone, Khurana (2013): Pharmacology of myopia and potential role for intrinsic retinal circadian rhythms. Exp Eye Res. 2013 Sep;114:35-47. doi: 10.1016/j.exer.2013.01.001. PMID: 23313151; PMCID: PMC3636148.

  41. Iuvone, Tosini, Pozdeyev, Haque, Klein, Chaurasia (2005): Circadian clocks, clock networks, arylalkylamine N-acetyltransferase, and melatonin in the retina. Prog Retin Eye Res. 2005 Jul;24(4):433-56.

  42. Lockley, Brainard, Czeisler (2003): High sensitivity of the human circadian melatonin rhythm to resetting by short wavelength light. J Clin Endocrinol Metab. 2003 Sep;88(9):4502-5. doi: 10.1210/jc.2003-030570. PMID: 12970330.

  43. Provencio, Rodriguez, Jiang, Hayes, Moreira, Rollag (2000): A novel human opsin in the inner retina. J Neurosci. 2000 Jan 15;20(2):600-5. doi: 10.1523/JNEUROSCI.20-02-00600.2000. PMID: 10632589; PMCID: PMC6772411.

  44. Lupi, Oster, Thompson, Foster (2008): The acute light-induction of sleep is mediated by OPN4-based photoreception. Nat Neurosci. 2008 Sep;11(9):1068-73. doi: 10.1038/nn.2179. PMID: 19160505.

  45. Meijer, Michel, Vansteensel (2007): Processing of daily and seasonal light information in the mammalian circadian clock. Gen Comp Endocrinol. 2007 Jun-Jul;152(2-3):159-64. doi: 10.1016/j.ygcen.2007.01.018. PMID: 17324426. REVIEW

  46. Hemmings, Greengard, Tung, Cohen (1984): DARPP-32, a dopamine-regulated neuronal phosphoprotein, is a potent inhibitor of protein phosphatase-1. Nature. 1984 Aug 9-15;310(5977):503-5. doi: 10.1038/310503a0. PMID: 6087160.

  47. Svenningsson, Nishi, Fisone, Girault, Nairn, Greengard (2004): DARPP-32: an integrator of neurotransmission. Annu Rev Pharmacol Toxicol. 2004;44:269-96. doi: 10.1146/annurev.pharmtox.44.101802.121415. PMID: 14744247. REVIEW